Is Bristol-Myers Squibb’s Stock Rally Justified? Bull Vs. Bear Analysts On Q2 Earnings
Bristol-Myers Squibb Co (NYSE:BMY) on Friday reported upbeat second-quarter results.
The report came amid an exciting earnings season. Here are some key analyst takeaways.
Barclays On Bristol-Myers Squibb
Analyst Carter Gould downgraded the rating to Underweight, while maintaining the price target at $41.
Gould explained the downgrade, stating that the recent rally in Bristol-Myers Squibb’s stock, “despite little movement in underlying post-2025 fundamentals,” appears to be “an over-reaction to the IRA news.”
The company second-quarter beat was “at best mixed, if not low-quality – driven by legacy products and stocking dynamics,” the analyst stated. Bristol-Myers Squibb’s persistent broader challenge remains the same, which is “eroding top-line and EPS post-2026 …
Full story available on Benzinga.com
